I. Introduction lavonoids represent one of major polyphenolic groups, which are widely distributed in the plant kingdom and commonly found in vegetables, fruits and teas of the human diet 1 . These compounds have shown low toxicity as well as a variety of physiological effects 1 . In the past few decades, these naturally occurring compounds have attracted much attention by reported beneficial effects on health, such as antioxidant, antitumor, anti-inflammatory and anti-allergic effects 2 , as well as presenting low toxicity to human organism 1,3 . In midst the various classes of flavonoids, the flavonols have been the focus of many in vitro and in vivo studies for their diversified actions on numerous biological pathways 1 . Structurally, flavonoids are composed of a basic flavylium cation, with three phenolic rings 4 . Flavonols present subtle molecular changes to the main ring (Ring C), with the addition of a hydroxyl group (OH) on the third carbon, and a carbonyl group (C=O) on carbon fourth 1,5 . Many reports have shown that structure changes of flavonoid molecules result in variations of bioavailability, by changing absorption efficiency and pathways; thus, also altering biological effects and creating action mechanisms specificity 1,4,[6][7][8] . Flavonoids neuroprotective effects are mostly bound to its related antioxidant, anti-proliferative and anti-inflammatory properties 9,10 . The Central Nervous System (CNS) is highly exposed to oxidative damage, due to high oxygen consumption, high levels of unsaturated lipids and presence of transitional metals 1 . In addition, because of inefficient antioxidant defense mechanisms, alterations of neuronal organic homeostasis can cause grave repercussions 1,9 . Antioxidant properties are correlated since oxidative stress and lipid peroxidation have been linked to a range of neurological pathologies, such as brain trauma, ischemia and neurodegenerative disorders 2,11,12 . Thus, flavonoids ability to scavenge ROS and inhibit lipid peroxidation, protecting neuronal cells from oxidative damage, may be used to prevent and treat neurological pathologies 2 .Neurodegenerative disorders, such as Alzheimer, Parkinson's and Huntington's disease cause a progressive functional alteration of neuronal systems 13 . Worldwide, they present variable incidence and constantly relate to high morbidity rates, higher cost in health care and social impairment [13][14][15] . These pathologies have been well studied; however, new advances in physiopathology and, therefore, in therapeutic modalities are infrequent, maintaining no cure or reversible treatments. Other flavonoids, such as resveratrol, fisetin and hyperin have also been considered as potential drugs with neuroprotective effects 9,13,[16][17][18][19][20][21][22] . Recent studies verified, different flavonoids act on specific organic pathways 1 , yet comparable studies between flavonoids are rare. Resveratrol, as an example, has shown neurological and cognitive enhancement properties in a clinical trial 23 . Quercetin and rutin have been widely investigated as therapeutic drugs, especially concerning anti-proliferative and antioxidant effects, for many diseases, including CNS pathologies. However, neuroprotective potential of flavonoids in human trials has been poorly addressed, and Isoquercitrin has rarely been implied in studies investigating neuroprotective effects and comparison studies of the same subject. # II. Methods/Research # b) Literature Evidence Evidence Based Medicine (EBM) is a systematic analysis of present-day research and scientific findings, in which obtained information is classified by authenticity and Evidence Level results 24 . Thus creating a hierarchy system to evaluate information and incorporate in a practical environment of research, as well as to support the conduct of clinical care and therapeutic options 25 . Recommendation levels are the results of extensive research analysis and an important guide to practitioner's clinical decisions 26 . Although animal experiments have always contributed to our understanding of drug action mechanisms and pathophysiological aspects of many diseases 27 , some authors debate on whether animal researches are valuable predictors of human conditions and pathogenesis, due to interspecies differences and lack of uniform requirements for reporting animal data and comparable results 28 . Considering the pyramid of medical research, animal experimentation and in vitro studies take their place at the bottom, reflecting basic studies; however, tools of assessment of these studies have emerged in the last decade to improve transparency and accuracy of reports 29 . One of which, ARRIVE guidelines (Animals in Research: Reporting in Vivo Experiments)creates a checklist of 20 steps to be met during animal experimentation reports 29 . Although ARRIVE checklist is not mentioned in many animal reports, in the past five years endorsement of this tool amongst journals has risen considerably 30 , becoming an important source of evaluation. Thus, it was this paper's intent to grade Animal Experimentation and In Vitro Studies´ Evidence Level, through a personal classification (Table 1), derived from the Oxford Centre for Evidence Based Medicine (CEBM). In addition, apply the ARRIVE checklist toin vivo animal studies referenced in this paper. # c) Flavonoids Flavonoids represent one of major polyphenolic groups, which are widely distributed in the plant kingdom and commonly found in vegetables, fruits and teas of the human diet 1 . Recent experimental studies and clinical trials conducted with flavonoids, in particular the class of flavonols, have demonstrated a wide variety of physiological effects, including antioxidant, antiproliferative/antitumor and anti-inflammatory, also correlating some of their action mechanisms to neuroprotective potential. Thus evidencing this class of molecules as an accessible alternative of preventive therapy or treatment of numerous neurological diseases. Flavonoids can be found in nature as aglycone forms, glycosides or methylated/acylated derivatives 1 . Amongst flavonols representatives, the best-known molecules are (1) Quercetin, an important aglycone form and a pioneer subject mid flavonoid research; (2) Rutin, main hydrophilic glycoside molecule; and (3) Isoquercitrin (IQ), main lipophilic glycoside, also known as quercetin-3-O-glucoside (Q3G) and Isoquercetin, a nearly identical quercetin-3-monoglucoside 1,31 . Flavonoids absorption occur predominantly in the small intestine, however it is limited by molecular weight and hydrophilicity 1,31 . Few studies have been conducted as to elucidate bioavailability and absorption across the blood-brain barrierin human models 32,33 (Evidence Level 1B), whereas most studies have used in vivo animal models, biological differences and lack of complete physiological understanding of flavonoid's absorption in the small intestine,have limited new findings. Nevertheless, the type of sugar moiety attached to primary aglycone molecule, has been named the major determinant of small intestine absorption, rather than its position in the same molecule 34 . In food plants, quercetin occurs almost exclusively as glycosides, in which the and the dominant type of glycoside vary amongst foods and is usually located at the 3 or 4 position of the pyrone ring 1,34 . Onions, kale, broccoli and apples are important sources of glucoside molecules, such as Rutin 35 . IQ is a common naturally occurring glycoside also obtained by enzymatic hydrolysis of rutin with hesperedinase, an enzyme produced by specific types of fungisuch as Penicillium sp. Heperedinase has a ?-l-ramnosidase selective activity when applied at 58°C for 30 minutes, capable of cleaving the rhamnosidase radical of rutin's basic structure and leaving the glucoside radical intact, transforming it into IQ 36 . This procedure, generates what is called enzymatic modified IQ or Hydrolysed Rutin (HR), both of which consists of a mixture that includes IQ (69,5%), quercetin (7,5%), rutin and other small metabolites 36 . Studies have shown the superiority of anti-oxidant and anti-proliferative properties of HR when compared solely to quercetin and rutin (Evidence Level 2C) 36,37 . # III. Neurodegenerative Diseases Neurodegenerative diseases are a consequence of genetic and environmental factors that are strongly associated with age 38 . These disorders arise from multifactorial conditions that interfere directly with cellular oxidative homeostasis and function 38 . Amongst various pathophysiological factors, increased oxidative stress, mitochondrial dysfunction and abnormal protein dynamics represent a common role in the development of different neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS) 38 . Also appearing to command numerous neuronal pathways, leading to alterations in neurotransmission and ionic channels, protein aggregation, impaired bioenergetics and even cellular death 38 . Free radicals are indispensable molecules to cellular function by involvement in many biochemical activities 39 . However, oxidative stress arise from disturbances between pro-oxidant/antioxidant equilibrium 39 . Overproduction of free radicals produce cytotoxicity and genotoxicity by damaging biomolecules, such as proteins, lipids and DNA 39 and leading to arise of various chronic diseases, including in the CNS 39 . In the brain glial and neuronal cells are particularly sensitive to free radicals and actively targeted by ROS 39 . Primary neuroprotective potential of flavonoids rely mainly on their antioxidant effect and leading mechanism of action seems to be reduction of cellular oxidative stress by scavenging and decreasing reactive oxygen species (ROS) and reactive nitrogen species (RNS) in brain tissue(Evidence Level 2C) 2,9,[40][41][42][43] . Also exhibiting activation of anti-oxidant enzymes (Evidence Level 1B) 44 (Evidence Level 2C) 45,46 , protein disaggregation and diminished production (Evidence Level 2C) 47 , decrease of lipid peroxidation (Evidence Level 1B) 48 (Evidence Level 2C) 42 , transitional metal chelation (Evidence Level 2C e 4) 2,49-51 and antiinflammation effects (Evidence Level 1B) 52 . Although, Ansari et al. (2009) demonstrated in an in vitro study that quercetin showed dual effect on oxidative stress; at lower dosages, antioxidant effects were observed, though in higher dosages, it exhibited a pro-oxidant effect also increasing neuronal dysfunction, it is still clear flavonoids present oxidative-protective effects on various diseases, including those of the CNS. # a) Alzheimer's Disease Alzheimer's disease (AD) is a complex neurological disorder clinically characterized by progressive loss of memory and cognition; histopathology demonstrates accumulation of extracellular ?-amyloid plaques (major constituent of senile plaques), intracellular neurofibrillary tangles, tau protein phosphorylation and neurodegeneration of synaptic neurons, especially in the hippocampus 13,53 .Oxidative stress and neuroinflammation are also considered hallmarks of AD, mainly responsible for increasedneurotoxicity 54 of cognitive-modulating areas 55 . In addition, the decrease in cholinergic neurotransmission has also been implicated in cognitive decline and behavioral changes of AD 56 . Flavonoids represent an interesting class of phytochemicals and, even before scientific studies, have been widely used as phytotherapy medicines, like Ginkgo biloba, which includes quercetin and kaempferol 57 . In 2009, Shi et al. demonstrated quercetin molecule was responsible for high antioxidant activity of this plant extract, corroborating to the hypothesis of flavonoids, in particular flavonols, as possible therapeutic drugs with neuroprotective potential (Evidence Level 2C) 58 . A main pathophysiological mechanism of AD is the transformation of ?-amyloid peptides into amyloidbeta (Abeta) plaques and the extracellular aggregation of plaques in areas such as the hippocampus 47 , which appear to be an early phenomenon and is currently used as a diagnostic tool of the disease through PET scan markers (Evidence Level 2A) 59 . In the last few years, some studies have comprised flavonoid's neuroprotective potential and investigated antiamyloidogenic properties. Ansari et al. ( 2009) demonstrated quercetin's protective effect under low dosages (5 ?M and 10 ?M), strongly inhibiting Abeta fibril formation and preventing glutathione oxidation (Evidence Level2C) 60 . In 2011, Jimenez-Aliaga evaluated anti-amyloidogenic potential of both quercetin and rutin, demonstrating inhibition of Abeta fibrils formation and disaggregation by both compounds, however, noticing statistical superiority of quercetin's effects. Also reporting the reduction of ROS production and lipid peroxidation index (Evidence Level2C) 47 . In addition, Choi et al. (2014) studied thein vitro activity of a flavonoid panel, including quercetin and rutin, against Abeta-induced toxicity. Results corroborated previous studies showing that flavonoids significantly block A?induced neuronal toxicity(Evidence Level 2C) 61 . Liu et al., 2013 investigated in vivo the protective effects of quercetin against Abeta-induced toxicity, on both endothelial cells and neurons, after oral administration of quercetin for a period of 8 days; learning and memory were evaluated by Morris Water Maze test, and cerebral flow was closely monitored. Results showed neurovascular coupling protection, with reduction of oxidative stress and maintenance of neurovascular unit(Evidence Level 1D) 62 . Recent in vitro and in vivo studies investigated neuroprotective effects of quercetin on Abeta-induced toxicity models. Results showed quercetin improved cell viability, by diminishing neuronal and endothelial oxidative stress(Evidence Levels 2C, 1D) 63,64 , and the production of ROS and LDH were decreased, as an increase on superoxide dismutase occurred (Evidence Level2C) 63 . Mohebali et al., 2016 demonstrated both Rutin's and Quercetin's potential to down regulate inflammation-involved genes in AD(Evidence Level 1D.I) 65 . Moreover, Sabogal-Guáqueta et al., performed an in vivo study with quercetin (25mg/kg) i.p. administration, for 3 months,on triple transgenic AD model mice, observing a decrease of extracellular ?-amyloid deposition, as well as a reduction of tau phosphorylation, astrogliosis and microgliosis in the hippocampus and amygdala(Evidence Level 1D) 66 . Isolated, rutin has been less studied in AD over the years. In 2012, Javed et al. conducted the investigation of rutin's neuroprotective antioxidant effects in an in vivo intracerebroventricularstreptozotocin (ICV-STZ) induced toxicity model. Rutin was pre-administered orally (25mg/kg) for 3 weeks, and results indicated attenuation of STZ-induced inflammation by reducing the expression of cyclooxygenase-2 (COX-2), interleukin-8 (IL-8) and nuclear factor-kB, thus preventing neuro-inflammatory morphological changes in the hippocampus(Evidence Level 1D) 67 . In addition, recent studies that comprised rutin's antioxidant activity on Abeta-induced neurotoxicity showed the decrease of ROS and RNS as the main action mechanism, consequently reducing lipid peroxidation. Interestingly, rutin was also capable of diminishing glutathione levels and dependent enzymes, also downregulating astrocytosis and microgliosis and, therefore, proving to having similar effects to quercetin (Evidence Levels 1D) [68][69][70] . Another hallmark characteristic of AD is the decrease in cholinergic neurotransmission, which has been implicated in cognitive decline, leading to dementia, and behavioral disorders 56 . The increase on cholinergic neurotransmission is an important focus of recent drug therapy and comprises the inhibition of acetylcholinesterase (AchE), acetylcholine's degrading enzyme 71 . Both quercetin and rutin have been targets of recent studies focusing on AchE inhibition, since it is an important target on Alzheimer's drug therapy. Quercetin is a strong AchE inhibitor(Evidence Levels 1D, 2B.II) 72,73 , presenting higher binding strength to active site of the enzyme then some of the drugs in the market, like Donezepil 74 ; also acting in a dose-dependent manner(Evidence Level 3B) 42 . Rutin also seems to show AchE inhibition properties(Evidence Level 3B) 75 ,however no study has solely involved this compound. There are no studies indexed on PubMed or Scielo involving isoquercitrin's specific neuroprotective effects in AD. Nevertheless, IQ exhibits important antioxidant activity 76 and has been implied as a promising molecule for the treatment of several pathologies, especially cancer 77 . # b) Parkinson's Disease Parkinson's disease (PD) is a neurodegenerative movement disorder mainly characterized by progressive loss of dopaminergic neurons within nigrostriatal pathway, affecting substantia nigra area, and associated with microglial-mediated neuro-inflammation 22 . Pathogenic aspects of PD involve mitochondrial dysfunction, changes in micro-RNA and ?-synuclein levels 13 , a major constituent of Lewy bodies and a hallmark of PD 78 A associated as a risk factor for dopamine cellular degeneration of PD 79 , and mitochondrial dysfunction plays an important role on energetic balance as well as regulating oxidative and apoptotic pathways 38 . Quercetin has been widely investigated for its antioxidant effects; however, specific PD model investigations are scarce. On chronic rotenone (ROT)induced parkinsonian models quercetin (25-75mg/kg i.p.) showed reduced loss of ROT-induced dopaminergic neurons, also decreasing glutathione levels and increasing anti-oxidant enzymes (catalase and superoxide dismutase)(Evidence Level 2B) 80 . In 2015, Denny Joseph et al., also investigated on ROTinduced models the beneficial effects of treatment association between fish oil and quercetin. Results corroborated previous studies demonstrating significant behavioral change as well as attenuation of oxidative stress and mitochondrial dysfunction indicators (Evidence Level 1D ) 81 . Other studies using methyl-4-phenylpyridinium ion (MPP(+)), a parkinsonian toxin that provokes degeneration of dopaminergic neurons 82 , and 6hydroxydopamine (6-OHDA), a selective dopaminergic neurotoxin 83 . Also demonstrated quercetin's neuroprotective potential by reducing apoptotic neuronal death, through modulation of pro-apoptotic (Bax) and anti-apoptotic (Bcl-2) genes, and decreasing oxidative stress and neuro-inflammation (IL-1, TNF-? and COX-2) on microglial cells (Evidence Levels 2C, 2C, 1D, 1D) [82][83][84][85] . Although these results are consistent with literary review appointing quercetin as an antioxidant molecule, some studies have shown a paradoxical effect of this compound when used in high dosages (Evidence Level 2C) 60 . In addition, in 2015, Ahn et al. investigated quercetin's specific effect on ?-synuclein expression. During the experiment, PC12 cells were pre-treated with quercetin and results showed quercetin presents neuroprotective effects affecting various mechanisms such as apoptosis and oxidative stress; however, quercetin treatment increased ?-synuclein levels, and although cell viability and survival were unaltered with the up-expression, this data suggests quercetin's effects on PD is still not entirely understood(Evidence Level 2C) 78 . During the course of 2014 to 2016, Magalingam et al., produced a series of three articles investigating Rutin and Isoquercitrin on 6-OHDA PD-induced models. Both rutin and IQ demonstrated antioxidant effects by reducing lipid peroxidation and increasing anti-oxidant enzymes (catalase, superoxide dismutase and glutathione peroxidase) (Evidence Level 2C) [86][87][88] . Cytoprotective activity of IQ occurred in a dosedependent manner. Furthermore, Rutin showed upregulation of the TH gene, an important factor in dopamine biosynthesis; as well as modulation of apoptotic pathways by reducing Park2, Park5, Park7, Caspase 3 and Caspase 7 genes(Evidence Level 2C) 86 . # c) Huntington's Disease Huntington's disease (HD) is an autosomal dominant, progressive, neurodegenerative disorder clinically characterized by motor, cognitive and behavioral impairment, also presenting high morbidity and mortality rates 89 . Incidence is higher at European countries and mean age of symptoms onset occurs around 40 years old 90 . HD is cause by an expanded CAG trinucleotide repeat in the HTT gene, responsible for encoding the protein huntingtin. The mutation lead to the production of an abnormal protein with long polyglutamine sequences that confers toxic properties and predisposes protein fragmentation, which can result in neuronal death 91 . Quercetin is the only major flavonol whose neuroprotective effect has been associated to Huntington's disease treatment potential. In this review, we found no articles investigating rutin or isoquercitrin effects on HD models. In 2013, Sandhir et al. evaluated oral supplementation of quercetin (25mg/kg) on 3nitropropionic acid-induced (3-NP) Huntington's disease animal model. Posterior analysis was conducted on mitochondrial biogenetics, oxidative stress, neurobiological behaviors and histopathological assays. It was proven quercetin exhibits protective effects by attenuating mitochondrial oxidative stress (reduced lipid peroxidation and mitochondrial swelling), as well as increasing motor skills and antioxidant elements (Evidence Level 2B) 92 . Additionally, in 2014, quercetin was once again tested on 3-NP-induced HD models, confirming previous results of antioxidant properties and motor coordination increase, along with display of behavioral changes throughlessening of anxiety and isolation;also reducing neuro-inflammatory responses with an increase of astrocyte numbers in core lesions and decreased microglial proliferation (Evidence Level 1D) 93,94 . # Volume XVII Issue I Version I # IV. Conclusion Flavonoids have been widely investigated in the past decades and have shown a wide variety of physiological effects, determining a therapeutic potential on innumerous diseases, including neurological pathologies. Their neuroprotective effects are mostly related to anti-oxidant and anti-inflammatory properties; however, specific mechanisms have been reached on both in vitro and in vivo animal models of neurodegenerative diseases. It is quite difficult to assess on whether animal experimentation is most likely to predict human outcomes and toxicity, nonetheless, it is a vital part of scientific research and discovery. Evidence-based medicine analyses such studies in order to foresee favorable outcomes, and although most studies conducted with flavonols are in vitro and animal models of experimentation (Evidence Level 1D/2B and 2C), ARRIVE guidelines offer a tool of assessment, in which the goal is to improve transparency and accuracy of these reports. Our findings on the subject suggest in vitro studies are still the majority of literature references, yet in vivo animal experimentation references seems to be well-constructed(Table 2) and able to provide key results, leading to the possibility of human clinical trials. Despite the lack of human trials with Quercetin, Rutin and Isoquercitrin, other flavonoids have been tested and results show neurological features, providing a glimpse of the therapeutic potential of these compounds. We also suggest Isoquercitrin as a viable option to future experiments, due to its superiority of anti-oxidant and anti-proliferative properties. # Volume XVII Issue I Version I 1LEVELTHERAPY1ASystematic Reviews of Randomized Controlled Trials (RCT)1BIndividual RCT with narrow Confidence Interval1CAll or None Studies1D*In Vivo Animal Trials2ASystematic Reviews of Cohort Studies2B*I. Cohort Studies (In Human) II. Ex Vivo Studies2C*Outcome Research or Ecological Studies or In Vitro Studies3ASystematic Review of Case-Control Studies3B*Case-Control Studies or Drug Biological Characteristics Assessment Studies4*Case-series and poor quality cohort and case-control studies or Literature Review5Expert opinion without explicit critical appraisal*Modified items from Oxford CEBM 2Year 2017 © 2017 Global Journals Inc. (US) © 2017 Global Journals Inc. (US) Ungemach FR, Cermak R. Oral bioavailability of * Evaluating the Bioavailability of Isoquercetin JAppleton Nat Med J 2 1 2010 * A quest for staunch effects of flavonoids: Utopian protection against hepatic ailments ADhiman ANanda SAhmad 10.1016/j.arabjc.2012.05.001 Arabian Journal of Chemistry 2012 Published * Flavonoids and Wnt/?catenin signaling: potential role in colorectal cancer therapies NGAmado DPredes MMMoreno IOCarvalho Mendes F A JGAbreu 10.3390/ijms150712094 Int J Mol Sci 15 7 2014 * Dietary flavonols: chemistry, food content, and metabolism SAAherne NMO'brien Nutrition 18 1 2002 * Antioxidant activity of flavonol aglycones and their glycosides in methyl linoleate AHopia MHeinonen doi:10. 1007/s11746-999-0060-0 J Am Oil Chem Soc 76 1 1999 * Flavonoid antioxidants: Chemistry, metabolism and structureactivity relationships KEHeim ARTagliaferro DJBobilya 10.1016/S0955-2863(02)00208-5 J Nutr Biochem 13 10 2002 * Phenolic Composition and Antioxidant Activity of Malus domestica Leaves MLiaudanskas PVi?kelis RRaudonis DKviklys NUselis VJanulis 10.1155/2014/3062 Sci World J 2014 17 2014 * quercetin from different quercetin glycosides in dogs MReinboth SWolffram GAbraham doi:10.1017/ S000711451000053X Br J Nutr 104 2 2010 * Neuroprotective effects of berry fruits on neurodegenerative diseases SSubash MMEssa SAl-Adawi MAMemon TManivasagam MAkbar doi: 10. 4103/1673-5374.139483 Neural Regen Res 9 16 2014 * Mechanisms of Neuroprotection by Quercetin: Counteracting Oxidative Stress and More LGCosta JMGarrick PJRoque CPellacani doi:10.1155 Oxid Med Cell Longev 2986796 2016. 2016. 2016/2986796 * Biological activity of quercetin-3-Oglucoside, a known plant flavonoid SMRazavi SZahri GZarrini HNazemiyeh SMohammadi 10.1134/S1068162009030133 Bioorg Khim 35 3 2009 * Protective effects of extracts and flavonoids isolated from scutia buxifolia reissek against chromosome damage in human lymphocytes exposed to hydrogen peroxide AABoligon MRSagrillo LFMachado 10.3390/molecules17055757 Molecules 17 5 2012 * Polyphenols: multipotent therapeutic agents in neurodegenerative diseases KSBhullar HpvRupasinghe 10.1155/2013/891748 Oxid Med Cell Longev 891748 2013. 2013 * Use of liquid chromatography with electrochemical detection for the determination of antioxidants in less common fruits ZGazdik VReznicek VAdam doi:10. 3390/molecules131102823 Molecules 13 11 2008 * Neurodegenerative diseases: From available treatments to prospective herbal therapy ISolanki PParihar MSParihar doi:10.1016/ j.neuint.2015.11.001 Neurochem Int 2015 * KZeng XWang HFu GLiu Protective effects and mechanism of hyperin on CoCl2-induced PC12 cells * Zhongguo Zhong Yao Za Zhi 36 17 2011 * Modulation of neurotrophic signaling pathways by polyphenols FMoosavi RHosseini LSaso OFiruzi doi:10.2147/ DDDT.S96936 Drug Des Devel Ther 10 2015 * Neuroprotective Effect of Fisetin Against Amyloid-Beta-Induced Cognitive/Synaptic Dysfunction, Neuroinflammation, and Neurodegeneration in Adult Mice AAhmad TAli HYPark HBadshah SURehman KimMo 10.1007/s12035-016-9795-4 Mol Neurobiol 2016 * Neuroprotective and anti-inflammatory effects of flavonoids isolated from Rhus verniciflua in neuronal HT22 and microglial BV2 cell lines NCho JHChoi HYang 10.1016/j.fct.2012.03.052 Food Chem Toxicol 50 6 2012 * Nutraceutical antioxidants as novel neuroprotective agents NAKelsey HMWilkins DALinseman doi:10.3390/ molecules15117792 Molecules 15 11 2010 * Resveratrol attenuates L-DOPA-induced hydrogen peroxide toxicity in neuronal cells CSPeritore AHo BKYamamoto SESchaus 10.1097/WNR.0b013e32835a4ea4 Neuroreport 23 17 2012 * Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation GBureau FLongpre M-GMartinoli 10.1002/jnr.21503 J Neurosci Res 86 2 2008 * Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults AVWitte LKerti DSMargulies AFlöel 10.1523/JNEUROSCI.0385-14.2014 J Neurosci 34 23 2014 * Evidence Based Medicine -New Approaches and Challenges IMasic MMiokovic BMuhamedagic 10.5455/aim.2008.16.219-225 Acta Inform Medica 18 1 219 2008 * The Levels of Evidence and Their Role in Evidence-Based Medicine PBBurns RJRohrich KCChung 10.1097/PRS.0b013e318219c171 Plast Reconstr Surg 128 1 2011 * Níveis de evidência e graus de recomendação da medicina baseada em evidências Medeiros L Stein A Rev AMRIGS 46 2002 * Can Animal Models of Disease Reliably Inform Human Studies HBVan Der Worp DWHowells ESSena doi:10. 1371/journal.pmed.1000245 PLoS Med 7 3 e1000245 2010 * Is animal research sufficiently evidence based to be a cornerstone of biomedical research? PPound MBBracken 10.1136/bmj.g3387 BMJ 348 may30 1 2014 * Study Designs in Medicine NSut 10.5152/balkanmedj.2014.1408 Balkan Med J 31 4 2015 * Surge in support for animal-research guidelines DCressey 10.1038/nature.2016.19274 Nature 2016 * Efficiency of absorption and metabolic conversion of quercetin and its glucosides in human intestinal cell line Caco-2 KMurota SShimizu HChujo JHMoon JTerao 10.1006/abbi.2000.2123 Arch Biochem Biophys 384 2 2000 * Comparison of quercetin pharmacokinetics following oral supplementation in humans DKaushik KO'fallon PMClarkson CPDunne KRConca BMichniak-Kohn J Food Sci 2012 * 10.1111/j.1750-3841.2012.02934.x 77 * Dose-response to 3 months of quercetin-containing supplements on metabolite and quercetin conjugate profile in adults LCialdella-Kam DCNieman WSha MPMeaney AMKnab RAShanely 10.1017/S0007114512003972 Br J Nutr 109 11 2013 * The type of sugar moiety is a major determinant of the small intestinal uptake and subsequent biliary excretion of dietary quercetin glycosides IcwArts AlaSesink MFaassen-Peters PchHollman 10.1079/BJN20041123 Br J Nutr 91 6 2004 * Flavonols, flavones and flavanols -nature, occurrence and dietary burden PCHollman ICArts doi:10. 1002/(SICI)1097-0010 J Sci Food Agric 80 7 2000. 20000515 7<1081::AID-JSFA566>3.0.CO;2-G * Enzymatic de-glycosylation of rutin improves its antioxidant and antiproliferative activities MembDe Araújo MoreiraFranco YEAlberto TG doi:10.1016/j. foodchem.2013.02.127 Food Chem 141 1 2013 * Isoquercitrin is the most effective antioxidant in the plant Thuja orientalis and able to counteract oxidative-induced damage to a transformed cell line (RGC-5 cells) SHJung BJKim EHLee Nn ;Osborne SSheikh Safia EHaque SSMir 10.1016/j.neuint.2010.08.005.38 doi:10.1155/2013/563481 J Neurodegener Dis 57 7 2010. 2013 Neurochem Int. * Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options BUttara ASingh PZamboni RMahajan 10.2174/157015909787602823 Curr Neuropharmacol 7 1 2009 * Health promotion by flavonoids , tocopherols , tocotrienols , and other phenols : direct or indirect effects ? Antioxidant or not ? 1 -4 BHalliwell JRafter AJenner Am J Clin Nutr 81 2005 * Neuroprotective properties of Spanish red wine and its isolated polyphenols on astrocytes SMartin EGonzalez-Burgos MECarretero MPGomez-Serranillos 10.1016/j.foodchem.2011.02.074 Food Chem 128 1 2011 * In vitro antioxidant and cholinesterase inhibitory activities of methanolic fruit extract of Phyllanthus acidus MMoniruzzaman MAsaduzzaman MSHossain 10.1186/s12906-015-0930-y BMC Complement Altern Med 15 403 2015 * Antioxidant activities of flavonol derivatives from the leaves and stem bark of Scutia buxifolia Reiss AABoligon RPPereira ACFeltrin doi:10.1016/j. biortech.2009.03.091 Bioresour Technol 100 24 2009 * Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis AWBoots MDrent VcjDe Boer ABast GrmmHaenen 10.1016/j.clnu.2011.01.010 Clin Nutr 30 4 2011 * Neuroprotective effects of phytosterols and flavonoids from Cirsium setidens and Aster scaber in human brain neuroblastoma SK-N-SH cells MJChung SLee YPark Il JLee KHKwon 10.1016/j.lfs.2016.02.035 Life Sci 2016 * Neuroprotective effect of quercetin against oxidative damage and neuronal apoptosis caused by cadmium in hippocampus MKanter CUnsal CAktas MErboga 10.1177/0748233713504810 Toxicol Ind Health 32 3 2016 * Quercetin and rutin exhibit antiamyloidogenic and fibril-disaggregating effects in vitro and potent antioxidant activity in APPswe cells KJimenez-Aliaga PBermejo-Bescos JBenedi SMartin-Aragon doi:10. 1016/j.lfs.2011.09.023 Life Sci 89 25-26 2011 * Effect of resveratrol and quercetin supplementation on redox status and inflammation after exercise LSMcanulty LEMiller PAHosick ACUtter JCQuindry SRMcanulty 10.1139/apnm-2012-0455 Appl Physiol Nutr Metab 38 7 2013 * Evaluation of radioprotective activities Rhodiola imbricata Edgew--a high altitude plant RArora RChawla RSagar Mol Cell Biochem 273 1-2 2005 * Prospective neurobiological effects of the aerial and root extracts and some pure compounds of randomly selected Scorzonera species FSSenol OBAcikara GSCitoglu IEOrhan SDall' Acqua FOzgokce doi:10.31 09/13880209.2013.872152 Pharm Biol 52 7 2014 * Flavonoids and their oxidation products protect efficiently albumin-bound linoleic acid in a model of plasma oxidation CDufour MLoonis 10.1016/j.bbagen.2007.02.005 Biochim Biophys Acta -Gen Subj 1770 6 2007 * Supplementation of the Pure Flavonoids Epicatechin and Quercetin Affects Some Biomarkers of Endothelial Dysfunction and Inflammation in (Pre)Hypertensive Adults: A Randomized Double-Blind, Placebo-Controlled, Crossover Trial JIDower JMGeleijnse LGijsbers CSchalkwijk DKromhout PCHollman 10.3945/jn.115.211888 J Nutr 145 7 2015 * Pathogenesis of Alzheimer's disease RHSwerdlow Clin Interv Aging 2 3 2007 * Neuroprotective role of natural polyphenols CSpagnuolo MNapolitano ITedesco SMoccia AMilito GLRusso Curr Top Med Chem 2016 * Oxidative stress: emerging mitochondrial and cellular themes and variations in neuronal injury GCHiggins PMBeart YSShin MJChen NSCheung PNagley 10.3233/JAD-2010-100321 J Alzheimers Dis 20 2 2010 Suppl * Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease CGParsons WDanysz ADekundy IPulte 10.1007/s12640-013-9398-z Neurotox Res 24 3 2013 * Ginkgo biloba leave extract: biological, medicinal, and toxicological effects P-CChan QXia PPFu doi:10.1080/ 10590500701569414 J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 25 3 2007 * Protective effects of Ginkgo biloba extract (EGb761) and its constituents quercetin and ginkgolide B against beta-amyloid peptide-induced toxicity in SH-SY5Y cells CShi LZhao BZhu doi:10.1016/j. cbi.2009.05.010 Chem Biol Interact 181 1 2009 * Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis EMorris AChalkidou AHammers JPeacock JSummers SKeevil 10.1007/s00259-015-3228-x Eur J Nucl Med Mol Imaging 43 2 2016 * Protective effect of quercetin in primary neurons against Abeta(1-42): relevance to Alzheimer's disease MAAnsari HMAbdul GJoshi WOOpii DAButterfield 10.1016/j.jnutbio.2008.03.002 J Nutr Biochem 20 4 2009 * Effects of Flavonoid Compounds on beta-amyloid-peptideinduced Neuronal Death in Cultured Mouse Cortical Neurons S-MChoi BCKim Y-HCho 10.4068/cmj.2014.50.2.45 Chonnam Med J 50 2 2014 * Quercetin protects against the Abeta(25-35)-induced amnesic injury: involvement of inactivation of rage-mediated pathway and conservation of the NVU RLiu TZhang DZhou doi:10. 1016/j.neuropharm.2012.11.018 Neuropharmacology 67 2013 * Quercetin protects human brain microvascular endothelial cells from fibrillar beta-amyloid1-40-induced toxicity YLi SZhou JLi 10.1016/j.apsb.2014.12.003 Acta Pharm Sin B 5 1 2015 * Quercetin reduces eIF2? phosphorylation by GADD34 induction MHayakawa MItoh KOhta 10.1016/j.neurobiolaging.2015.05.006 Neurobiol Aging 36 9 2015 * Effect of flavonoids rich extract of Capparis spinosa on inflammatory involved genes in amyloid-beta peptide injected rat model of Alzheimer's disease NMohebali ShahzadehFazeli SAGhafoori H 10.1080/1028415X.2016.1238026 Nutr Neurosci 2016 * The flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice AMSabogal-Guáqueta JIMuñoz-Manco JRRamírez-Pineda MLamprea-Rodriguez EOsorio GPCardona-Gómez 10.1016/j.neuropharm.2015.01.027 Neuropharmacology 93 2015 * Rutin prevents cognitive impairments by ameliorating oxidative stress and neuroinflammation in rat model of sporadic dementia of Alzheimer type HJaved MMKhan AAhmad 10.1016/j.neuroscience.2012.02.046 Neuroscience 210 2012 * The n-Butanol Fraction and Rutin from Tartary Buckwheat Improve Cognition and Memory in an In Vivo Model of Amyloid-beta-Induced Alzheimer's Disease JYChoi JMLee DGLee 10.1089/jmf.2014.3292 J Med Food 18 6 2015 * Rutin improves spatial memory in Alzheimer's disease transgenic mice by reducing Abeta oligomer level and attenuating oxidative stress and neuroinflammation P-XXu S-WWang X-LYu doi:10.1016/ j.bbr.2014.02.002 Behav Brain Res 264 2014 * Rutin activates the MAPK pathway and BDNF gene expression on beta-amyloid induced neurotoxicity in rats SMoghbelinejad MNassiri-Asl TNFarivar doi:10. 1016/j.toxlet.2013.10.010 Toxicol Lett 224 1 2014 * MBColovic DZKrstic TDLazarevic-Pasti AMBondzic VmAcetylcholinesteraseVasic Inhibitors 10.2174/1570159X11311030006 Pharmacology and Toxicology. Curr Neuropharmacol 11 3 2013 * Quercetin protects the impairment of memory and anxiogenic-like behavior in rats exposed to cadmium: Possible involvement of the acetylcholinesterase and Na(+), K(+)-ATPase activities FHAbdalla RSchmatz AMCardoso 10.1016/j.physbeh.2014.06.008 Physiol Behav 135 2014 * Hypothyroidism Enhanced Ectonucleotidases and Acetylcholinesterase Activities in Rat Synaptosomes can be Prevented by the Naturally Occurring Polyphenol Quercetin JBaldissarelli ASanti RSchmatz 10.1007/s10571-016-0342-7 Cell Mol Neurobiol 2016 * In silico QSAR analysis of quercetin reveals its potential as therapeutic drug for Alzheimer's disease MRIslam AZaman IJahan RChakravorty SChakraborty 10.1016/j.jyp.2013.11.005 J Young Pharm 5 4 2013 * Anticholinesterase and antioxidant investigations of crude extracts, subsequent fractions, saponins and flavonoids of atriplex laciniata L.: potential effectiveness in Alzheimer's and other neurological disorders ZKamal FUllah MAyaz 10.1186/s40659-015-0011-1 Biol Res 48 21 2015 * Antioxidant and cytotoxic studies for kaempferol, quercetin and isoquercitrin JcrVellosa LORegasini NMKhalil 10.1590/S0100-46702011000200001 Eclet Quim 36 2 2011 * Review of anticancer mechanisms of isoquercitin COrfali G Di ACDuarte VBonadio 10.5306/wjco.v7.i2.189 World J Clin Oncol 7 2 189 2016 * The role of quercetin on the survival of neuron-like PC12 cells and the expression of alpha-synuclein T-BAhn JeonBs 10.4103/1673-5374 Neural Regen Res 10 7 106 2015 * Oxidized quercetin inhibits ?-synuclein fibrillization MZhu SHan ALFink 10.1016/j.bbagen.2012.12.027 Biochim Biophys Acta 1830 4 2013 * Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson's disease in rats SSKaruppagounder SKMadathil MPandey RHaobam URajamma KPMohanakumar doi:10.1016/j. neuroscience.2013.01.032 Neuroscience 236 2013 * Combined oral supplementation of fish oil and quercetin enhances neuroprotection in a chronic rotenone rat model: relevance to Parkinson's disease DennyJoseph KM Muralidhara 10.1007/s11064-015-1542-0 Neurochem Res 40 5 2015 * Protective effects of resveratrol and quercetin against MPP+ -induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons JBournival PQuessy M-GMartinoli doi:10. 1007/s10571-009-9411-5 Cell Mol Neurobiol 29 8 2009 * Quercetin exerts a neuroprotective effect through inhibition of the iNOS/NO system and proinflammation gene expression in PC12 cells and in zebrafish ZJZhang LcvCheang MWWang Sm-YLee 10.3892/ijmm.2010.571 Int J Mol Med 27 2 2011 * Quercetin and sesamin protect dopaminergic cells from MPP+-induced neuroinflammation in a microglial (N9)-neuronal (PC12) coculture system JBournival MPlouffe JRenaud CProvencher M-GMartinoli 10.1155/2012/921941 Oxid Med Cell Longev 2012 921941 2012 * Effect of quercetin and desferrioxamine on 6-hydroxydopamine (6-OHDA) induced neurotoxicity in striatum of rats NHaleagrahara CJSiew KPonnusamy J Toxicol Sci 38 1 2013 * Protective effects of flavonol isoquercitrin, against 6-hydroxy dopamine (6-OHDA)-induced toxicity in PC12 cells KBMagalingam ARadhakrishnan NHaleagrahara 10.1186/1756-0500-7-49 BMC Res Notes 7 49 2014 * Quercetin glycosides induced neuroprotection by changes in the gene expression in a cellular model of Parkinson's disease KBMagalingam ARadhakrishnan PRamdas NHaleagrahara 10.1007/s12031-014-0400-x J Mol Neurosci 55 3 2015 * Protective effects of quercetin glycosides, rutin, and isoquercetrin against 6-hydroxydopamine (6-OHDA)-induced neurotoxicity in rat pheochromocytoma (PC-12) cells KBMagalingam ARadhakrishnan NHaleagrahara 10.1177/0394632015613039 Int J Immunopathol Pharmacol 29 1 2016 * Huntington's disease: from molecular pathogenesis to clinical treatment CARoss SJTabrizi 10.1016/S1474-4422 Lancet Neurol 10 1 2011 * Huntington's disease MjuNovak SJTabrizi 10.1136/bmj.c3109 BMJ 340 jun30 4 2010 * Huntington disease. Nat Rev Dis Prim GPBates RDorsey JFGusella doi:10. 1038/nrdp.2015.5 2015 15005 * Quercetin supplementation is effective in improving mitochondrial dysfunctions induced by 3-nitropropionic acid: implications in Huntington's disease RSandhir AMehrotra doi: 10.1016/ j.bbadis. 2012.11.01 8 Biochim Biophys Acta 1832 3 2013 * Combination of lycopene, quercetin and poloxamer 188 alleviates anxiety and depression in 3-nitropropionic acid-induced DJain AGangshettiwar * Huntington's disease in rats doi:10.5455/ jice.20140903012921 J Intercult Ethnopharmacol 3 4 2014 * Quercetin improves behavioral deficiencies, restores astrocytes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington's Disease JChakraborty RSingh DDutta ANaskar URajamma KPMohanakumar 10.1111/cns.12189 CNS Neurosci Ther 20 1 2014